

## References

### I-4

1. Corifact® (factor XIII concentrate (human) for intravenous use [package insert]. CSL Behring LLC. Kankakee, IL. Revised 12/2019.
2. The National Hemophilia Foundation. MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders. MASAC Document #253.
3. Hoots W, Shapiro A. Treatment of hemophilia. *UpToDate*. 2015.
4. Alphanate® (antihemophilic factor (human)) for intravenous use [package insert]. Grifols Biologicals, Inc. Los Angeles, CA. Revised 03/2021.
5. Humate-P® (antihemophilic factor (human)) for intravenous use [package insert]. CSL Behring LLC. Kankakee, IL. Revised 06/2020.
6. Wilate® (antihemophilic factor (human)) for intravenous use [package insert]. Octapharma USA Inc. Hoboken, NJ. Revised 03/2020.
7. NovoSeven® RT (coagulation factor VIIa (recombinant) for intravenous use [package insert]. Novo Nordisk Inc. Plainsboro, NJ. Revised 07/2020.
8. Hemofil M® (antihemophilic factor (human)) for intravenous use [package insert]. Baxter Healthcare Corp. Westlake Village, CA. Revised 03/2023.
9. Koāte®-DVI (antihemophilic factor (human)) for intravenous use [package insert]. Kedrion Biopharma, Inc. Fort Lee, NJ. Revised 01/2022.
10. Advate® (antihemophilic factor (recombinant)) for intravenous use [package insert]. Baxter Healthcare Corp. Westlake Village, CA. Revised 03/2023.
11. Kogenate® FS (antihemophilic factor (recombinant)) for intravenous use [package insert]. Bayer HealthCare LLC. Whippany, NJ. Revised 12/2019.
12. Recombinate® (antihemophilic factor (recombinant)) for intravenous use [package insert]. Baxter Healthcare Corp. Westlake Village, CA. Revised 03/2023.
13. Xyntha® (antihemophilic factor (recombinant)) for intravenous use [package insert]. Wyeth Pharmaceuticals Inc. Philadelphia, PA. Revised 07/2022.
14. FEIBA® (anti-inhibitor coagulant complex) for intravenous use [package insert]. Baxter Healthcare Corporation. Westlake Village, CA.. Revised 03/2023.
15. AlphaNine® SD (coagulation Factor IX) for intravenous use [package insert]. Grifols Biologicals Inc. Los Angeles, CA. Revised 03/2021.
16. Mononine® (coagulation factor IX) for intravenous use [package insert]. CSL Behring LLC. Kankakee, IL. Revised 12/2018.
17. Profilnine® (factor IX complex) for intravenous use [package insert]. Grifols Biologicals Inc. Los Angeles, CA. Revised 06/2018.
18. BeneFIX® (coagulation factor IX (recombinant)) for intravenous use [package insert]. Wyeth Pharmaceuticals Inc. Philadelphia, PA.. Revised 11/2022.
19. Novoeight® (antihemophilic factor (recombinant)) for intravenous use [package insert]. Novo Nordisk Inc. Plainsboro, NJ. Revised 07/2020.
20. Kovaltry® (antihemophilic Factor (Recombinant)) for intravenous use [package insert]. Bayer Healthcare LLC. Whippany, NJ. Revised 12/2022
21. Adynovate® (antihemophilic Factor (Recombinant), PEGylated) for intravenous use [package insert]. Baxalta US Inc. Westlake Village, CA. Revised 03/2023.

22. Nuwiq® (antihemophilic factor, recombinant) for intravenous use [package insert]. Octapharma USA, Inc. Hoboken, NJ. Revised 06/2021.
23. Afstyla® (antihemophilic Factor (Recombinant)) for intravenous use [package insert]. CSL Behring LLC. Kankakee, IL. Revised 04/2021.
24. Ixinity® (coagulation factor IX (recombinant)) for intravenous use [package insert]. BioSolutions Inc. Baltimore, MD. Revised 11/2022.
25. Rixubis® (coagulation factor IX (recombinant) for intravenous use [package insert]. Baxter Healthcare Corporation West Lake Village, CA.. Revised 03/2023.
26. Coagadex® (coagulation Factor X (Human)) for intravenous use [package insert]. Bio Products Laboratory USA, Inc. Durham, NC. Revised 11/2020.
27. Obizur® (antihemophilic factor (recombinant), porcine sequence) for intravenous use [package insert]. Baxter Healthcare Corp., Westlake Village, CA. Revised 03/2023.
28. Eloctate® (antihemophilic factor (recombinant), Fc fusion protein) for intravenous use [package insert]. Biogen Idec Inc. Cambridge, MA. Revised 12/2020.
29. Vonvendi® (von Willebrand factor complex (recombinant)) for intravenous use [package insert]. Baxalta US Inc. Westlake Village, CA. Revised 03/2023.
30. Alprolix™ (coagulation factor IX (recombinant), Fc fusion protein) for intravenous use [package insert]. Bioverativ Therapeutics Inc. Waltham, MA. Revised 10/2020.
31. Idelvion® (coagulation Factor IX (Recombinant)) for intravenous use [package insert]. CSL Behring LLC. Kankakee, IL. Revised 07/2021.
32. Tretten® (coagulation factor XIII A-subunit (recombinant)) for intravenous use [package insert]. Novo Nordisk Inc. Plainsboro, NJ. Revised 06/2020.
33. RiaSTAP® (fibrinogen concentrate (human)) for intravenous use [package insert]. Kankakee, IL. CSL Behring LLC. Revised 06/2021.
34. Cyklokapron® (inhibitor of plasminogen activation) for intravenous use [package insert]. Pfizer Inc. New York, NY. Revised 03/2021.
35. Rebinyn® (Coagulation Factor IX (Recombinant), GlycoPEGylated) for intravenous use [package insert]. Novo Nordisk Inc. Plainsboro, NJ. Revised 08/2022.
36. Hayes Inc. Prognosis Overview. Hemlibra (Emicizumab-kxwh). March 2018. Accessed May 17, 2018.
37. Clinical Pharmacology™ Compendium. 2023. Tampa FL: Gold Standard, Inc. Factor IX.
38. Clinical Pharmacology™ Compendium. 2023. Tampa FL: Gold Standard, Inc. Factor VII a, Recombinant.
39. Clinical Pharmacology™ Compendium. 2023. Tampa FL: Gold Standard, Inc. Factor X.
40. Clinical Pharmacology™ Compendium. 2023. Tampa FL: Gold Standard, Inc. Factor Xa.
41. Clinical Pharmacology™ Compendium. 2023. Tampa FL: Gold Standard, Inc. Factor XIII A-Subunit, Recombinant.
42. Clinical Pharmacology™ Compendium. 2023. Tampa FL: Gold Standard, Inc. Factor XIII Concentrate.
43. Pai M, Key NS, Skinner M, Curtis R, Feinstein M, Kessler C, et al. Guideline on care models for hemophilia management. *Haemophilia*. 2016. 22(2):6-16.
44. Hemlibra (emicizumab-kxwh) injections, for subcutaneous use [package insert]. Genentech Inc. South San Francisco, CA. Revised 03/2023.
45. Clinical Pharmacology™ Compendium. 2023. Tampa FL: Gold Standard, Inc. Emicizumab.
46. Micromedex DrugDex Compendium®. 2023. Emicizumab.

47. Fibryga, Fibrinogen concentrate (human), for intravenous use [package insert]. Octapharma USA Inc. Hoboken, NJ. Revised 12/2020.
48. Clinical Pharmacology™ Compendium. 2023. Tampa FL: Gold Standard, Inc. Fibrinogen Concentrate, Human.
49. . Micromedex DrugDex Compendium®. 2023. Fibrinogen Concentrate, Human.
50. Jivi, antihemophilic factor (recombinant), pegylated-aucl, for intravenous use [package insert]. Bayer Healthcare LLC. Whippany, NJ. Revised 08/2018.
51. Clinical Pharmacology™ Compendium. 2023. Tampa FL: Gold Standard, Inc. AHF, Factor VIII.
52. Micromedex DrugDex Compendium®. 2023. Antihemophilic factor, Factor VIII.
53. Tarantino MD, Pindolia VK. Hemophilia management via data collection and reporting: initial findings from the comprehensive care sustainability collaborative. *J Manag Care Spec Pharm*. 2017; 23(1):51-56.
54. Esperoct (recombinant antihemophilic factor, glycopegylated-exei) lyophilized powder for solution, for intravenous use [package insert]. Novo Nordisk. Plainsboro, NJ. Revised 08/2022.
55. Stoffman J, Andersson NG, Branchford B, et al. Common themes and challenges in hemophilia care: a multinational perspective. *Hematology*. 2019;24(1):39-48.
56. Tegenge MA, Mahmood I, Forshee R. Clinical pharmacology review of plasma-derived and recombinant protein products: CBER experience and perspectives on model-informed drug development. *Haemophilia*. 2019;25(4):e240-e246.
57. Peyvandi F, Tavakkoli F, Frame D, et al. Burden of mild haemophilia A: systematic literature review. *Haemophilia*. 2019;25(5):755-763.
58. Sevenfact (coagulation factor VIIa [recombinant]-jnew) lyophilized powder for solution, for intravenous use [package insert]. HEMA Biologics, LLC. Louisville, KY. Revised 11/2022.
59. Altuviio™ [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehlt], [package insert] for intravenous use Bioverativ Therapeutics Inc. Waltham, MA. 02/2023.
60. von Drygalski A, Chowdary P, Kulkarni R, Susen S, Konkle BA, Oldenburg J, Matino D, Klamroth R, Weyand AC, Jimenez-Yuste V, Nogami K, Poloskey S, Winding B, Willemze A, Knobe K; XTEND-1 Trial Group. Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A. *N Engl J Med*. 2023;388(4):310-318.
61. Micromedex DrugDex Compendium®. 2023. Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehlt
62. Clinical Pharmacology™ Compendium. 2023. Tampa FL: Gold Standard, Inc. Antihemophilic Factor, Fc Fusion Protein, Recombinant